Moneycontrol PRO
Open App
you are here: HomeNewsTrendsHealth

Merck says its antiviral pill less effective in final analysis

The lower efficacy is a disappointment for the drug, known as molnupiravir, which health officials around the world are counting on as a critical tool to save lives and reduce the burden on hospitals.

November 27, 2021 / 09:24 AM IST
Merck says its antiviral pill less effective in final analysis

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. (Representative image: Reuters)

Rebecca Robbins Pharmaceutical company Merck said on November 26 that in a final analysis of a clinical trial, its antiviral pill reduced the risk of hospitalization and death among high-risk COVID-19 patients by 30 percent, down from an earlier estimate of 50 percent. The lower efficacy is a disappointment for the drug, known as molnupiravir, which health officials around the world are counting on as a critical tool to save lives and reduce the burden on hospitals. It increases the importance of a similar,...

  • PRO Panorama

    Moneycontrol Pro Panorama | When boring is good news for the Street

    Sep 30, 2022 / 02:25 PM IST

    RBI chooses to stick to the rate hike narrative, markets leap 1,000 points

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers